Skip to content

AptarGroup

US · ATR #1713 by market cap Listed 1970
140.08 -0.26 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Company notice
    Astron Corp Ltd (Delisted): Application for quotation of securities - ATR
    ASX · 2026/4/1
  • Rating change
    Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $145
    Market Newswire · 2026/6/12
  • Company notice
    Astron Corp Ltd (Delisted): Application for quotation of securities - ATR
    ASX · 2026/6/2
  • Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models
    PR Newswire · 2026/11/10
  • BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating
    Market Newswire · 2026/10/31
  • UBS Maintains AptarGroup(ATR.US) With Hold Rating, Raises Target Price to $142
    Market Newswire · 2026/11/3
  • Company notice
    AI: Statutory ex post facto disclosure documents (merger) (ATR-Trek Co., Ltd.)
    JPX · 2025/9/1
  • Rating change
    Raymond James Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $160
    Market Newswire · 2026/7/15
  • Rating change
    BofA Securities Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $173
    Market Newswire · 2026/7/14
  • Rating change
    BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $154
    Market Newswire · 2026/10/6
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (ATR) and Contineum Therapeutics, Inc. Class A (CTNM)
    TipRanks · 2026/7/31
  • Company notice
    Astron Corp Ltd (Delisted): Application for quotation of securities - ATR
    ASX · 2026/5/18
  • Rating change
    Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155
    Market Newswire · 2026/10/19
  • Company notice
    AI: Statutory Advance Disclosure Documents (merger) (ATR-Trek Co., Ltd.)
    JPX · 2025/7/22
  • BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155
    Market Newswire · 2026/11/2
  • Rating change
    Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $155
    Market Newswire · 2026/8/3
  • Rating change
    BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $172
    Market Newswire · 2026/8/21
  • Rating change
    Deutsche Bank Initiates AptarGroup(ATR.US) With Buy Rating, Announces Target Price $150
    Market Newswire · 2026/10/7
  • UBS Initiates AptarGroup(ATR.US) With Hold Rating, Announces Target Price $135
    Market Newswire · 2026/10/9
  • Rating change
    William Blair Maintains AptarGroup(ATR.US) With Hold Rating
    Market Newswire · 2026/7/31
  • Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients With Rashes Due to KRAS and MEK Inhibitors
    PR Newswire · 2026/10/29
  • Rating change
    Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $145
    Market Newswire · 2026/5/4
  • Earnings Flash (ATR) AptarGroup, Inc. Posts Q3 Adjusted EPS $1.52 per Share, Vs. FactSet Est of $1.47
    MT Newswires · 2026/10/30
  • Rating change
    DBS Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $170
    Market Newswire · 2026/3/19
  • Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $155
    Market Newswire · 2026/10/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

AptarGroup discussion 0 comments

Add a comment